Lexaria Bioscience Receives Cannabis R&D License from Health Canada

KELOWNA, BC / ACCESSWIRE / August 13, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“RD”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed.

Lexaria’s new cannabis RD license is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECHTM infusions as well as including two different methodologies by which the Company can create nano-sized molecules when deemed beneficial and is currently operational.

https://finance.yahoo.com/news/lexaria-bioscience-receives-cannabis-r-101500534.html

by

Leave a Reply